Financial Survey: Enliven Therapeutics (NASDAQ:ELVN) and RAPT Therapeutics (NASDAQ:RAPT)

Enliven Therapeutics (NASDAQ:ELVN) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Enliven Therapeutics and RAPT Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	0	0	2	1	3.33
RAPT Therapeutics	0	9	2	0	2.18

Enliven Therapeutics currently has a consensus target price of $33.00, suggesting a potential upside of 53.35%. RAPT Therapeutics has a consensus target price of $21.57, suggesting a potential upside of 773.34%. Given RAPT Therapeutics’ higher possible upside, analysts clearly believe RAPT Therapeutics is more favorable than Enliven Therapeutics.

Profitability

This table compares Enliven Therapeutics and RAPT Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-28.83%	-27.05%
RAPT Therapeutics	N/A	-72.61%	-62.99%

Valuation and Earnings

This table compares Enliven Therapeutics and RAPT Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$71.58 million	($1.93)	-11.15
RAPT Therapeutics	$1.53 million	56.35	-$116.80 million	($3.07)	-0.80

Enliven Therapeutics has higher earnings, but lower revenue than RAPT Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Enliven Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500.

Summary

Enliven Therapeutics beats RAPT Therapeutics on 8 of the 12 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About RAPT Therapeutics

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company